$SMMT · Summit Therapeutics Inc.
Summit Therapeutics disclosed on November 15, 2026 that the FDA issued a Complete Response Letter for the ivonescimab BLA in EGFR-mutant NSCLC. The FDA determined substantial evidence of effectiveness is not established without a statistically significant OS improvement. The HARMONi Phase III trial met its PFS primary endpoint but OS showed only a positive trend, with a post-hoc hazard ratio of 0.76.
- FDA CRL rejects ivonescimab BLA for EGFR-mutant NSCLC after prior EGFR TKI therapy.
- FDA: PFS benefit without statistically significant OS does not support positive benefit-risk profile.
- HARMONi met PFS primary endpoint but OS showed only a positive trend, not statistical significance.
- Post-hoc analysis showed OS hazard ratio of 0.76 in full, Asian, and western populations.
- Summit continues five Phase III programs and multiple collaborations for ivonescimab in other indications.
Extended-hours last trade $11.53, down 18.52% vs regular close of $14.15, reflecting the CRL's rejection of the lead U.S. approval path.
The FDA rejection of Summit's lead U.S. filing removes a near-term catalyst and pressures the $11.29B market cap on a single-asset story.
The CRL underscores FDA's insistence on OS benefit in EGFR-mutant NSCLC, a high bar no approved regimen has met in this setting.
The CRL blocks near-term U.S. commercialization of ivonescimab in this indication and raises uncertainty about the broader development program's regulatory prospects.